MARGINAL ZONE LYMPHOMA

This study tests obinutuzumab, a targeted antibody, in 56 people with newly diagnosed marginal zone lymphoma who cannot have or have failed local therapy. The goal is to see if this drug can shrink tumors effectively without the harsh side effects of chemotherapy. Participants re…

This early-phase study tests a new type of CAR T-cell therapy that targets three different markers on cancer cells (CD19, CD20, and CD22) for people with B-cell lymphomas that have come back or not responded to standard treatments. About 15 adults will receive the therapy to see …

This study tests a combination of two drugs, acalabrutinib and tafasitamab, in 26 people with marginal zone lymphoma that has returned or not responded to prior treatment. The goal is to see if the combo can shrink or control the cancer. Participants receive treatment for up to 2…

This study tests whether combining two immunotherapy drugs, glofitamab and obinutuzumab, can safely control follicular lymphoma and marginal zone lymphoma in people who have not had prior treatment. About 47 participants will receive the drug combination. The main goal is to see …

This study tests whether adding two drugs (tafasitamab and lenalidomide) to standard rituximab therapy helps people with relapsed follicular or marginal zone lymphoma live longer without their cancer getting worse. About 654 adults who have already tried at least one prior treatm…

This study tests a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma (a type of blood cancer). About 175 participants will receive the treatment to see how many achieve complete remission at 12 months and how long they stay cancer-…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This study tests a new chemotherapy-free treatment for marginal zone lymphoma, a slow-growing blood cancer. It combines two drugs, Copanlisib and Rituximab, to see if they can control the disease better than Rituximab alone, while avoiding harsh chemo side effects. The trial incl…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This study tests a new drug called nemtabrutinib (formerly ARQ 531) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to prior therapy. The goal is to see if the drug is safe and can shrink or control the cancer. Parti…

This early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with certain aggressive lymphomas (Richter's transformation or transformed non-Hodgkin lymphoma). The main goals are to find the safest dose and see how well the drugs work together. Abou…

This study tests a drug called epcoritamab in Japanese adults with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug helps the immune system attack cancer cells. The study has two parts: first, finding a safe dose, and…

This study tracks 50 people who previously received an experimental CAR T cell therapy for certain lymphomas. The goal is to watch for long-term side effects and check how well patients do over 15 years. No new treatment is given, but patients can receive other cancer therapies d…

This study reviews medical records and PET scans from nearly 500 people with marginal zone lymphoma to see how well PET scans help doctors stage the disease and predict how patients will do. Researchers will compare PET results with CT scans and other tests. The goal is to improv…